Solid Biosciences Inc. — Director's Dealing 2018

Dec 5, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Solid Biosciences Inc. (SLDB)
CIK: 0001707502
Period of Report: 2018-12-03

Reporting Person: Quiroz Jorge Armando (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-12-03	Common Stock	S	1200	$29.9364	Disposed	267042	Direct
2018-12-03	Common Stock	S	6154	$30.208	Disposed	260888	Direct
2018-12-03	Common Stock	S	31426	$31.4118	Disposed	229462	Direct
2018-12-03	Common Stock	S	1370	$32.2441	Disposed	228092	Direct

Footnotes

F1: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2018.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.90 to $29.99, inclusive. The reporting person undertakes to provide to the issuer, any
security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.97, inclusive. The reporting person undertakes to provide to the issuer, any
security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.01 to $31.98, inclusive. The reporting person undertakes to provide to the issuer, any
security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.56, inclusive. The reporting person undertakes to provide to the issuer, any
security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form.